Article PMID,Article title,Article keywords,Article MESH identifiers,Article Year,Author full name,Author email,Affiliation name,Affiliation zipcode,Country,Institution GRID name,Institution GRID id,Match status
31644467,Common and rare forms of vasculitis associated with Sjögren's syndrome.,[''],[''],2019,Argyropoulou Ourania D,,"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.",,Greece,,,False
31642912,The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.,"['\n          18F-FDG PET/CT', 'Systemic sclerosis', 'interstitial lung disease', 'lung fibrosis', 'positron emission tomography']",[''],2019,Peelen Daphne M,,"Department of Rheumatology, Amsterdam Rheumatology & Immunology Center.",,,,,False
31642912,The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.,"['\n          18F-FDG PET/CT', 'Systemic sclerosis', 'interstitial lung disease', 'lung fibrosis', 'positron emission tomography']",[''],2019,Zwezerijnen Ben G J C,,Department of Radiology and Nuclear Medicine.,,,,,False
31642912,The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.,"['\n          18F-FDG PET/CT', 'Systemic sclerosis', 'interstitial lung disease', 'lung fibrosis', 'positron emission tomography']",[''],2019,Nossent Esther J,,"Department of Pulmonary Medicine and Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.",,,,,False
31642912,The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.,"['\n          18F-FDG PET/CT', 'Systemic sclerosis', 'interstitial lung disease', 'lung fibrosis', 'positron emission tomography']",[''],2019,Meijboom Lilian J,,Department of Radiology and Nuclear Medicine.,,,,,False
31642912,The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.,"['\n          18F-FDG PET/CT', 'Systemic sclerosis', 'interstitial lung disease', 'lung fibrosis', 'positron emission tomography']",[''],2019,Hoekstra Otto S,,Department of Radiology and Nuclear Medicine.,,,,,False
31642912,The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.,"['\n          18F-FDG PET/CT', 'Systemic sclerosis', 'interstitial lung disease', 'lung fibrosis', 'positron emission tomography']",[''],2019,Van der Laken Conny J,,"Department of Rheumatology, Amsterdam Rheumatology & Immunology Center.",,,,,False
31642912,The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.,"['\n          18F-FDG PET/CT', 'Systemic sclerosis', 'interstitial lung disease', 'lung fibrosis', 'positron emission tomography']",[''],2019,Voskuyl Alexandre E,,"Department of Rheumatology, Amsterdam Rheumatology & Immunology Center.",,,,,False
31635810,Clinical ultrasonography in systemic autoimmune diseases.,"['Clinical ultrasonography', 'Ecografía clínica', 'Enfermedades autoinmunes sistémicas', ""Sjögren's syndrome"", 'Systemic autoimmune diseases', 'Síndrome de Sjögren', 'Vasculitis']",[''],2019,Serralta San Martín G,gonzaloserralta@mac.com,"Servicio de Medicina Interna, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes (Madrid), España. Electronic address: gonzaloserralta@mac.com.",,,,,False
31635810,Clinical ultrasonography in systemic autoimmune diseases.,"['Clinical ultrasonography', 'Ecografía clínica', 'Enfermedades autoinmunes sistémicas', ""Sjögren's syndrome"", 'Systemic autoimmune diseases', 'Síndrome de Sjögren', 'Vasculitis']",[''],2019,Canora Lebrato J,,"Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, Fuenlabrada (Madrid), España.",,,Hospital Universitario de Fuenlabrada,grid.411242.0,True
31634487,Primary Sjögren's syndrome and the eye.,"['Primary Sjögren syndrome', 'dry eye disease', 'inflammation', 'lacrimal gland', 'treatment']",[''],2019,Bjordal Oddbjørn,,"Department of Ophthalmology, Østfold Hospital, Grålum, Norway.",,Norway,,,False
31634487,Primary Sjögren's syndrome and the eye.,"['Primary Sjögren syndrome', 'dry eye disease', 'inflammation', 'lacrimal gland', 'treatment']",[''],2019,Norheim Katrine Brække,,"Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.",,Norway,,,False
31634487,Primary Sjögren's syndrome and the eye.,"['Primary Sjögren syndrome', 'dry eye disease', 'inflammation', 'lacrimal gland', 'treatment']",[''],2019,Rødahl Eyvind,,"Department of Ophthalmology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.",,Norway,Haukeland University Hospital,grid.412008.f,True
31634487,Primary Sjögren's syndrome and the eye.,"['Primary Sjögren syndrome', 'dry eye disease', 'inflammation', 'lacrimal gland', 'treatment']",[''],2019,Jonsson Roland,,"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Rheumatology, Haukeland University Hospital, Bergen, Norway.",,Norway,Haukeland University Hospital,grid.412008.f,True
31634487,Primary Sjögren's syndrome and the eye.,"['Primary Sjögren syndrome', 'dry eye disease', 'inflammation', 'lacrimal gland', 'treatment']",[''],2019,Omdal Roald,roald.omdal@lyse.net,"Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway; Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway. Electronic address: roald.omdal@lyse.net.",,Norway,,,False
31632334,Muscular Tuberculosis: A New Case and a Review of the Literature.,"['biopsy', 'muscle', 'muscular tuberculosis', 'pathology', 'tuberculosis']",[''],2019,Zeng Yanping,,"Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China.",,China,Wuhan University,grid.49470.3e,True
31632334,Muscular Tuberculosis: A New Case and a Review of the Literature.,"['biopsy', 'muscle', 'muscular tuberculosis', 'pathology', 'tuberculosis']",[''],2019,Liu Yin,,"Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China.",,China,Wuhan University,grid.49470.3e,True
31632334,Muscular Tuberculosis: A New Case and a Review of the Literature.,"['biopsy', 'muscle', 'muscular tuberculosis', 'pathology', 'tuberculosis']",[''],2019,Xie Yanchun,,"Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China.",,China,Wuhan University,grid.49470.3e,True
31632334,Muscular Tuberculosis: A New Case and a Review of the Literature.,"['biopsy', 'muscle', 'muscular tuberculosis', 'pathology', 'tuberculosis']",[''],2019,Liang Jingjing,,"Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China.",,China,Wuhan University,grid.49470.3e,True
31632334,Muscular Tuberculosis: A New Case and a Review of the Literature.,"['biopsy', 'muscle', 'muscular tuberculosis', 'pathology', 'tuberculosis']",[''],2019,Kuang Jiabing,,"Department of Orthopedic, Wuhan Fourth Hospital, Wuhan, China.",,China,,,False
31632334,Muscular Tuberculosis: A New Case and a Review of the Literature.,"['biopsy', 'muscle', 'muscular tuberculosis', 'pathology', 'tuberculosis']",[''],2019,Lu Zuneng,,"Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China.",,China,Wuhan University,grid.49470.3e,True
31632334,Muscular Tuberculosis: A New Case and a Review of the Literature.,"['biopsy', 'muscle', 'muscular tuberculosis', 'pathology', 'tuberculosis']",[''],2019,Zhou Yu,,"Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China.",,China,Wuhan University,grid.49470.3e,True
31631415,Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome.,[''],[''],2019,Bartoloni Elena,,"Rheumatology Unit, Department of Medicine, University of Perugia, Italy.",,Italy,,,False
31631415,Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome.,[''],[''],2019,Baldini Chiara,,"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.",,Italy,,,False
31631415,Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome.,[''],[''],2019,De Vita Salvatore,,"Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Italy.",,Italy,University of Udine,grid.5390.f,True
31631415,Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome.,[''],[''],2019,Priori Roberta,,"Rheumatology Unit, Sapienza University, Rome, Italy.",,Italy,,,False
31631415,Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome.,[''],[''],2019,Giacomelli Roberto,,"Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.",,Italy,University of L'Aquila,grid.158820.6,True
31631415,Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome.,[''],[''],2019,Bini Vittorio,,"Internal Medicine, Endocrinal and Metabolic Science, University of Perugia, Italy.",,Italy,,,False
31631415,Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome.,[''],[''],2019,Gerli Roberto,,"Rheumatology Unit, Department of Medicine, University of Perugia, Italy.",,Italy,,,False
31622314,Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.,"[""Aseptic meningitis, Keratoconjunctivitis sicca, Sjogren's syndrome. doi:10.5455/JPMA.295727\n""]",[''],2019,Basheer Asma,,"Department of Pediatrics, Shifa International Hospital, Islamabad, Pakistan.",,Pakistan,Shifa International Hospital,grid.415704.3,True
31622314,Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.,"[""Aseptic meningitis, Keratoconjunctivitis sicca, Sjogren's syndrome. doi:10.5455/JPMA.295727\n""]",[''],2019,Khan Ejaz Ahmed,,"Department of Pediatrics, Shifa International Hospital, Islamabad.",,,Shifa International Hospital,grid.415704.3,True
31622314,Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.,"[""Aseptic meningitis, Keratoconjunctivitis sicca, Sjogren's syndrome. doi:10.5455/JPMA.295727\n""]",[''],2019,Hashmi Tahir,,"Department of Rheumatology, Shifa International Hospital, Islamabad, Pakistan.",,Pakistan,Shifa International Hospital,grid.415704.3,True
31622314,Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.,"[""Aseptic meningitis, Keratoconjunctivitis sicca, Sjogren's syndrome. doi:10.5455/JPMA.295727\n""]",[''],2019,Khan Rashid Ali,,"Department of Emergency Medicine, Shifa International Hospital, Islamabad, Pakistan.",,Pakistan,Shifa International Hospital,grid.415704.3,True
31622314,Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.,"[""Aseptic meningitis, Keratoconjunctivitis sicca, Sjogren's syndrome. doi:10.5455/JPMA.295727\n""]",[''],2019,Ahmad Arsalan,,"Department of Neurology, Shifa International Hospital, Islamabad, Pakistan.",,Pakistan,Shifa International Hospital,grid.415704.3,True
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Jousse-Joulin Sandrine,,"Rheumatology department, Cavale Blanche Hospital and Brest Occidentale University, INSERM UMR 1227, Brest, France.",,France,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Gatineau Florence,,"INSERM CIC 1412, Brest Medical University Hospital, Brest, France.",,France,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Baldini Chiara,,"Rheumatology unit, University of Pisa, Pisa, Italy.",,Italy,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Baer Alan,,"Department of Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.",21224,,Johns Hopkins University School of Medicine,grid.471401.7,True
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Barone Francesca,,"Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.",,,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Bootsma Hendrika,,"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.",,,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Bowman Simon,,"Department of Rheumatology, University Hospitals, Birmingham NHS Trust, Birmingham, UK.",,,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Brito-Zerón Pilar,,"Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain.",,Spain,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Cornec Divi,,"Rheumatology department, Cavale Blanche Hospital and Brest Occidentale University, INSERM UMR 1227, Brest, France.",,France,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Dorner Thomas,,"Department of Medicine, Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany.",,Germany,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,de Vita Salvatore,,"Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital ""Santa Maria della Misericordia"", Udine, Italy.",,Italy,University Hospital,grid.449710.f,True
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Fisher Benjamin,,"Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.",,,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Hammenfors Daniel,,"Department of Rheumatology, Haukeland University Hospital, Norway.",,Norway,Haukeland University Hospital,grid.412008.f,True
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Hammenfors Daniel,,"Department of Clinical Science - Section for Rheumatology, University of Bergen, Norway.",,Norway,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Jonsson Malin,,"Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway.",,Norway,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Mariette Xavier,,"Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique, Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France.",,France,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Milic Vera,,"Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, Serbia.",,Serbia,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Nakamura Hideki,,"Department of Immunology and Rheumatology, Unit of Advanced Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, 852-8501, Japan.",,Japan,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Ng Wan-Fai,,"Institute of Cellular Medicine, Newcastle University & NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, NE2 4HH, UK.",NE2 4HH,,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Nowak Emmanuel,,"INSERM CIC 1412, Brest Medical University Hospital, Brest, France.",,France,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Ramos-Casals Manuel,,"Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain.",,Spain,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Rasmussen Astrid,,"Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.",,,Oklahoma Medical Research Foundation,grid.274264.1,True
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Seror Raphaele,,"Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique, Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France.",,France,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Shiboski Caroline H,,"Department of Orofacial Sciences, School of Dentistry, University of California, San Francisco, California, USA.",,,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Nakamura Takashi,,"Department of Radiology and Cancer Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8588, Japan.",,Japan,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Vissink Arjan,,"Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.",,,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Saraux Alain,,"Rheumatology department, Cavale Blanche Hospital and Brest Occidentale University, INSERM UMR 1227, Brest, France.",,France,,,False
31618794,Weight of Salivary-Gland Ultrasonography compared to Other items of the 2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome.,"['Classification criteria', 'Diagnosis', 'Primary Sjögren', 'Salivary glands', 'Ultrasonography', 's syndrome']",[''],2019,Devauchelle-Pensec Valerie,,"Rheumatology department, Cavale Blanche Hospital and Brest Occidentale University, INSERM UMR 1227, Brest, France.",,France,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Gulli Francesca,,"Dipartimento di Medicina di Laboratorio, Ospedale Madre Giuseppina Vannini, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Napodano Cecilia,,"Istituto di Medicina Interna, Università Cattolica del Sacro Cuore, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Napodano Cecilia,,"Area di Gastroenterologia e Oncologia medica, Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Marino Mariapaola,,"Istituto di Patologia Generale, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.",00168,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Marino Mariapaola,,"Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Ciasca Gabriele,,"Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Ciasca Gabriele,,"Istituto di Fisica, Università Cattolica del Sacro Cuore, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Pocino Krizia,,"Istituto di Medicina Interna, Università Cattolica del Sacro Cuore, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Pocino Krizia,,"Area di Gastroenterologia e Oncologia medica, Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Basile Valerio,,"Dipartimento di Medicina di Laboratorio, Università di Tor Vergata, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Visentini Marcella,,"Dipartimento di Medicina Traslazionale e di Precisione, Università di Roma La Sapienza, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Stefanile Annunziata,,"Area Diagnostica di Laboratorio, Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Todi Laura,,"Istituto di Patologia Generale, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.",00168,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Todi Laura,,"Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,De Spirito Marco,,"Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,De Spirito Marco,,"Istituto di Fisica, Università Cattolica del Sacro Cuore, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Rapaccini Gian Ludovico,,"Istituto di Medicina Interna, Università Cattolica del Sacro Cuore, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Rapaccini Gian Ludovico,,"Area di Gastroenterologia e Oncologia medica, Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31618438,Serum Immunoglobulin Free Light Chain levels in Systemic Autoimmune Rheumatic Diseases.,"['B-lymphocytes', 'FLC', 'SARD', 'mini autoantibodies', 'mixed cryoglobulinaemia']",[''],2019,Basile Umberto,,"Area Diagnostica di Laboratorio, Fondazione Policlinico Universitario ""A. Gemelli"" - I.R.C.C.S, Rome, Italy.",,Italy,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Weißenberg Sarah Y,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Weißenberg Sarah Y,,"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Szelinski Franziska,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Szelinski Franziska,,"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Schrezenmeier Eva,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Stefanski Ana-Luisa,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Wiedemann Annika,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Rincon-Arevalo Hector,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Rincon-Arevalo Hector,,"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Rincon-Arevalo Hector,,"Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Instituto de Investigaciones Médicas, Universidad de Antioquia UdeA, Medellín, Colombia.",,Colombia,Instituto de Investigaciones Marinas,grid.419099.c,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Welle Anna,,"Department of Genetics and Epigenetics, Saarland University, Saarbrücken, Germany.",,Germany,Saarland University,grid.11749.3a,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Jungmann Annemarie,,"Department of Genetics and Epigenetics, Saarland University, Saarbrücken, Germany.",,Germany,Saarland University,grid.11749.3a,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Nordström Karl,,"Department of Genetics and Epigenetics, Saarland University, Saarbrücken, Germany.",,Germany,Saarland University,grid.11749.3a,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Walter Jörn,,"Department of Genetics and Epigenetics, Saarland University, Saarbrücken, Germany.",,Germany,Saarland University,grid.11749.3a,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Imgenberg-Kreuz Juliana,,"Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Nordmark Gunnel,,"Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Rönnblom Lars,,"Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Bachali Prathyusha,,"RILITE Research Institute, Charlottesville, VA, United States.",,United States,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Catalina Michelle D,,"RILITE Research Institute, Charlottesville, VA, United States.",,United States,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Grammer Amrie C,,"RILITE Research Institute, Charlottesville, VA, United States.",,United States,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Lipsky Peter E,,"RILITE Research Institute, Charlottesville, VA, United States.",,United States,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Lino Andreia C,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Lino Andreia C,,"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Dörner Thomas,,"Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.",,Germany,,,False
31616406,Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.,"['B cell receptor signaling', 'CD40', 'anergy', 'post-activation', ""primary Sjögren's syndrome"", 'rheumatoid arthritis', 'systemic lupus erythematosus', 'toll-like receptor 9']",[''],2019,Dörner Thomas,,"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany.",,Germany,,,False
31615914,Anti-centromere antibody positive Sjogren's syndrome is associated with worse sicca symptoms than primary Sjogren's syndrome alone.,[''],[''],2019,Li Yifan,,"From the Multidisciplinary Sjogren's Clinic. University Health Network, University of Toronto.",,,University of Toronto,grid.17063.33,True
31615914,Anti-centromere antibody positive Sjogren's syndrome is associated with worse sicca symptoms than primary Sjogren's syndrome alone.,[''],[''],2019,Bookman Arthur A M,,"From the Multidisciplinary Sjogren's Clinic. University Health Network, University of Toronto.",,,University of Toronto,grid.17063.33,True
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Kane B S,baidykane@gmail.com,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal. baidykane@gmail.com.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Niasse M,,"Department of Rheumatology, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Faye A,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Diack N D,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Djiba B,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Dieng M,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Sow M,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Ndao A C,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Diagne N,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Ndongo S,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31615546,"Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.","['Africa south of the Sahara', 'Case report', 'Macrophage activation syndrome', 'Sjögren’s syndrome']",[''],2019,Pouye A,,"Department of Internal Medicine, Cheikh Anta DIOP University, Dakar, Senegal.",,Senegal,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Combier Alice,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Nocturne Gaétane,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Henry Julien,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Belkhir Rakiba,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Pavy Stephan,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Le Tiec Clotilde,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Descamps Elise,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Seror Raphaele,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31613955,Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.,"['Sjögren’s syndrome', 'anti-drug antibodies', 'ofatumumab', 'rheumatoid arthritis', 'rituximab', 'safety', 'systemic lupus erythematosus']",[''],2019,Mariette Xavier,,"Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, INSERM UMR1184 Pharmacy, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.",,France,,,False
31612760,Type I renal tubular acidosis caused by Sjögren's syndrome with hypokalemia as the first symptom: a case report.,"['Sjögren’s syndrome', 'case report', 'exocrine dysfunction', 'hypokalemia', 'kidney damage', 'renal tubular acidosis']",[''],2019,Zhou Yanjun,,"Department of Neurology, The First People's Hospital of Zunyi & The Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China.",,China,Zunyi Medical University,grid.417409.f,True
31612760,Type I renal tubular acidosis caused by Sjögren's syndrome with hypokalemia as the first symptom: a case report.,"['Sjögren’s syndrome', 'case report', 'exocrine dysfunction', 'hypokalemia', 'kidney damage', 'renal tubular acidosis']",[''],2019,Huang Nanqu,,"Department of Neurology, The First People's Hospital of Zunyi & The Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China.",,China,Zunyi Medical University,grid.417409.f,True
31612760,Type I renal tubular acidosis caused by Sjögren's syndrome with hypokalemia as the first symptom: a case report.,"['Sjögren’s syndrome', 'case report', 'exocrine dysfunction', 'hypokalemia', 'kidney damage', 'renal tubular acidosis']",[''],2019,Cao Guangyu,,"Department of Neurology, The First People's Hospital of Zunyi & The Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China.",,China,Zunyi Medical University,grid.417409.f,True
31612760,Type I renal tubular acidosis caused by Sjögren's syndrome with hypokalemia as the first symptom: a case report.,"['Sjögren’s syndrome', 'case report', 'exocrine dysfunction', 'hypokalemia', 'kidney damage', 'renal tubular acidosis']",[''],2019,Luo Yong,,"Department of Neurology, The First People's Hospital of Zunyi & The Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China.",,China,Zunyi Medical University,grid.417409.f,True
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Takeshita Masaru,,"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Suzuki Katsuya,,"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Kaneda Yukari,,"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Yamane Humitsugu,,"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Ikeura Kazuhiro,,"Division of Oral and Maxillofacial Surgery, Department of Dentistry and Oral Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Sato Hidekazu,,"Division of Oral and Maxillofacial Surgery, Department of Dentistry and Oral Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Kato Shin,,"Division of Oral and Maxillofacial Surgery, Department of Dentistry and Oral Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Tsunoda Kazuyuki,,"Division of Oral and Maxillofacial Surgery, Department of Dentistry and Oral Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.",,Japan,,,False
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Arase Hisashi,,"Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.",,Japan,Osaka University,grid.136593.b,True
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Arase Hisashi,,"Laboratory of Immunochemistry, WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.",,Japan,Osaka University,grid.136593.b,True
31611218,"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.","['Anti-centromere antibody', 'Autoantibody', ""Sjögren's syndrome""]",[''],2019,Takeuchi Tsutomu,tsutake@z5.keio.jp,"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan tsutake@z5.keio.jp.",,Japan,,,False
31608194,Granulomatous Mastitis: A Rare Case with Sjogren's Syndrome and Complications.,"['granulomatous mastitis', 'mastitis', ""sjogren's syndrome""]",[''],2019,Yazigi George,,"Internal Medicine, University of Central Florida College of Medicine, Orlando, USA.",,,,,False
31608194,Granulomatous Mastitis: A Rare Case with Sjogren's Syndrome and Complications.,"['granulomatous mastitis', 'mastitis', ""sjogren's syndrome""]",[''],2019,Trieu Becca H,,"Miscellaneous, University of Central Florida College of Medicine, Orlando, USA.",,,,,False
31608194,Granulomatous Mastitis: A Rare Case with Sjogren's Syndrome and Complications.,"['granulomatous mastitis', 'mastitis', ""sjogren's syndrome""]",[''],2019,Landis Michael,,"Miscellaneous, University of Central Florida College of Medicine, Orlando, USA.",,,,,False
31608194,Granulomatous Mastitis: A Rare Case with Sjogren's Syndrome and Complications.,"['granulomatous mastitis', 'mastitis', ""sjogren's syndrome""]",[''],2019,Parikh Jignesh G,,"Pathology, Orlando VA Medical Center, Orlando, USA.",,,,,False
31608194,Granulomatous Mastitis: A Rare Case with Sjogren's Syndrome and Complications.,"['granulomatous mastitis', 'mastitis', ""sjogren's syndrome""]",[''],2019,Mangal Mamta,,"Internal Medicine, University of Central Florida College of Medicine/Orlando VA Medical Center, Orlando, USA.",,,,,False
31607022,[Primary Sjogren's syndrome associated pulmonary arterial hypertension: 20 new cases].,"['Achieving treatment goals', 'Baseline characteristics', 'Primary Sjogren′s syndrome', 'Pulmonary arterial hypertension', 'Right heart catheterization']",[''],2019,Zhao Y,,"Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin 300052, China.",30005,China,Tianjin Medical University General Hospital,grid.412645.0,True
31607022,[Primary Sjogren's syndrome associated pulmonary arterial hypertension: 20 new cases].,"['Achieving treatment goals', 'Baseline characteristics', 'Primary Sjogren′s syndrome', 'Pulmonary arterial hypertension', 'Right heart catheterization']",[''],2019,Wang H,,"Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin 300052, China.",30005,China,Tianjin Medical University General Hospital,grid.412645.0,True
31607022,[Primary Sjogren's syndrome associated pulmonary arterial hypertension: 20 new cases].,"['Achieving treatment goals', 'Baseline characteristics', 'Primary Sjogren′s syndrome', 'Pulmonary arterial hypertension', 'Right heart catheterization']",[''],2019,Chen M,,"Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin 300052, China.",30005,China,Tianjin Medical University General Hospital,grid.412645.0,True
31607022,[Primary Sjogren's syndrome associated pulmonary arterial hypertension: 20 new cases].,"['Achieving treatment goals', 'Baseline characteristics', 'Primary Sjogren′s syndrome', 'Pulmonary arterial hypertension', 'Right heart catheterization']",[''],2019,Zhang N,,"Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin 300052, China.",30005,China,Tianjin Medical University General Hospital,grid.412645.0,True
31607022,[Primary Sjogren's syndrome associated pulmonary arterial hypertension: 20 new cases].,"['Achieving treatment goals', 'Baseline characteristics', 'Primary Sjogren′s syndrome', 'Pulmonary arterial hypertension', 'Right heart catheterization']",[''],2019,Yang Z W,,"Department of Cardiology, Tianjin Medical University General Hospital, Tianjin 300052, China.",30005,China,Tianjin Medical University General Hospital,grid.412645.0,True
31607022,[Primary Sjogren's syndrome associated pulmonary arterial hypertension: 20 new cases].,"['Achieving treatment goals', 'Baseline characteristics', 'Primary Sjogren′s syndrome', 'Pulmonary arterial hypertension', 'Right heart catheterization']",[''],2019,Li D,,"Department of Imaging Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China.",30005,China,Tianjin Medical University General Hospital,grid.412645.0,True
31607022,[Primary Sjogren's syndrome associated pulmonary arterial hypertension: 20 new cases].,"['Achieving treatment goals', 'Baseline characteristics', 'Primary Sjogren′s syndrome', 'Pulmonary arterial hypertension', 'Right heart catheterization']",[''],2019,Wei W,,"Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin 300052, China.",30005,China,Tianjin Medical University General Hospital,grid.412645.0,True
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Kwon Jieun,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Surenkhuu Bayasgalan,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Raju Ilangovan,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Atassi Nour,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Mun Jessica,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Chen Yi-Fan,,"Center for Clinical and Translational Science, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Sarwar Monazzah Akbar,,"Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Rosenblatt Mark,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Pradeep Anubhav,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,An Seungwon,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Dhall Nikhil,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Mun Christine,,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.",,,,,False
31606460,Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.,"['ACPAs', 'Autoantibodies', 'Citrullination', 'Dry eye', 'GVHD', 'IVIG', 'NETs', 'Neutrophils', 'Pooled human immune globulin', ""Sjögren's syndrome""]",[''],2019,Jain Sandeep,jains@uic.edu,"Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: jains@uic.edu.",,,,,False
31604447,Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.,"['Dermatomyositis', 'Opportunistic infection', 'Polymyositis', 'Systemic lupus erythematosus', 'Systemic rheumatic disease']",[''],2019,Hsu Chung-Yuan,,"Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.",,,,,False
31604447,Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.,"['Dermatomyositis', 'Opportunistic infection', 'Polymyositis', 'Systemic lupus erythematosus', 'Systemic rheumatic disease']",[''],2019,Ko Chi-Hua,,"Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.",,,National Chung Hsing University,grid.260542.7,True
31604447,Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.,"['Dermatomyositis', 'Opportunistic infection', 'Polymyositis', 'Systemic lupus erythematosus', 'Systemic rheumatic disease']",[''],2019,Ko Chi-Hua,,"Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Yunlin, Taiwan.",,,,,False
31604447,Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.,"['Dermatomyositis', 'Opportunistic infection', 'Polymyositis', 'Systemic lupus erythematosus', 'Systemic rheumatic disease']",[''],2019,Wang Jiun-Ling,,"Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No.138, Sheng Li Road, 704, Tainan, Taiwan.",,,National Cheng Kung University,grid.64523.36,True
31604447,Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.,"['Dermatomyositis', 'Opportunistic infection', 'Polymyositis', 'Systemic lupus erythematosus', 'Systemic rheumatic disease']",[''],2019,Hsu Tsai-Ching,,"Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan.",,,Chung Shan Medical University,grid.411641.7,True
31604447,Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.,"['Dermatomyositis', 'Opportunistic infection', 'Polymyositis', 'Systemic lupus erythematosus', 'Systemic rheumatic disease']",[''],2019,Lin Chun-Yu,linchunyumed@gmail.com,"Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No.138, Sheng Li Road, 704, Tainan, Taiwan. linchunyumed@gmail.com.",,,National Cheng Kung University,grid.64523.36,True
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Jousse-Joulin Sandrine,joulin@chu,"Rheumatology, Brest University Hospital, Brest, France sandrine.jousse-joulin@chu-brest.fr.",,France,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,D'Agostino Maria Antonietta,,"Rheumatology Department, INSERM U1173, Laboratoire d'Excellenc, Paris, France.",,France,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Hočevar Alojzija,,"Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia.",,Slovenia,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Naredo Esperanza,,"Rheumatology, Severo Ochoa Hospital, Madrid, Spain.",,Spain,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Terslev Lene,,"Rheumatology, Glostrup University Hospital, Copenhagen, Denmark.",,Denmark,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Ohrndorf Sarah,,"Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.",,Germany,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Iagnocco Annamaria,,"Scienze Cliniche e Biologiche, Università degli Studi di Torino, Rome, Italy.",,Italy,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Schmidt Wolfgang A,,"Rheumatology, Medical Centre for Rheumatology Berlin Buch, Berlin, Germany.",,Germany,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Finzel Stephanie,,"Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Germany.",,Germany,University Medical Center Freiburg,grid.7708.8,True
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Alavi Zarrin,,"INSERM, CIC 1412, Brest University Hospital, Brest, France.",,France,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Bruyn George A W,,"MC Group Hospitals, Lelystad, The Netherlands.",,,,,False
31601631,Could we use salivary gland ultrasonography as a prognostic marker in Sjogren's syndrome? Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier ,"['B cells', ""sjøgren's syndrome"", 'ultrasonography']",[''],2019,Bruyn George A W,,"Reumakliniek Flevoland, Lelystad, The Netherlands.",,,,,False
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Ruiz-Romero Cristina,,"Grupo de Investigación de Reumatología (GIR), Unidad de Proteómica, INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS , Universidad de A Coruña , A Coruña 15006 , Spain.",15006,Spain,,,False
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Lam Maggie P Y,,"Department of Medicine, Division of Cardiology, Consortium for Fibrosis Research and Translation, Anschutz Medical Campus , University of Colorado Denver , Aurora , Colorado 80045 , United States.",80045,United States,University of Colorado Denver,grid.241116.1,True
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Nilsson Peter,,"Division of Affinity Proteomics, SciLifeLab, Department of Protein Science , KTH Royal Institute of Technology , Stockholm 17121 , Sweden.",17121,Sweden,,,False
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Önnerfjord Patrik,,"Department of Clinical Sciences, Section for Rheumatology and Molecular Skeletal Biology , Lund University , Lund 22184 , Sweden.",22184,Sweden,Lund University,grid.4514.4,True
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Utz Paul J,,"Division of Immunology and Rheumatology , Stanford University School of Medicine ; Palo Alto , California 94304 , United States.",94304,United States,Stanford University School of Medicine,grid.471392.a,True
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Van Eyk Jennifer E,,"Department of Medicine and The Heart Institute , Cedars-Sinai Medical Center , Los Angeles , California 90048 , United States.",90048,United States,Cedars-Sinai Medical Center,grid.50956.3f,True
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Venkatraman Vidya,,"Department of Medicine and The Heart Institute , Cedars-Sinai Medical Center , Los Angeles , California 90048 , United States.",90048,United States,Cedars-Sinai Medical Center,grid.50956.3f,True
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Fert-Bober Justyna,,"Department of Medicine and The Heart Institute , Cedars-Sinai Medical Center , Los Angeles , California 90048 , United States.",90048,United States,Cedars-Sinai Medical Center,grid.50956.3f,True
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Watt Fiona E,,"Arthritis Research UK Centre for Osteoarthritis Pathogenesis, Kennedy Institute of Rheumatology , University of Oxford , Oxford OX3 7FY , United Kingdom.",OX3 7FY,United Kingdom,,,False
31599600,Mining the Proteome Associated with Rheumatic and Autoimmune Diseases.,"['Human Proteome Project', 'autoimmune diseases', 'bioinformatics', 'osteoarthritis', 'rheumatic diseases']",[''],2019,Blanco Francisco J,,"Grupo de Investigación de Reumatología, INIBIC-Complejo Hospitalario Universitario de A Coruña, SERGAS , Departamento de Medicina Universidad de A Coruña , A Coruña 15006 , Spain.",15006,Spain,,,False
31597594,Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.,"['Interferon', 'RIG-I and ITPR3', ""Sjögren's syndrome"", 'miR-1248']",[''],2019,Jang Shyh-Ing,,"Sjögren's Syndrome and Salivary Gland Dysfunction Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.",,,National Institutes of Health,grid.94365.3d,True
31597594,Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.,"['Interferon', 'RIG-I and ITPR3', ""Sjögren's syndrome"", 'miR-1248']",[''],2019,Tandon Mayank,,"Sjögren's Syndrome and Salivary Gland Dysfunction Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.",,,National Institutes of Health,grid.94365.3d,True
31597594,Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.,"['Interferon', 'RIG-I and ITPR3', ""Sjögren's syndrome"", 'miR-1248']",[''],2019,Teos Leyla,,"Sjögren's Syndrome and Salivary Gland Dysfunction Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.",,,National Institutes of Health,grid.94365.3d,True
31597594,Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.,"['Interferon', 'RIG-I and ITPR3', ""Sjögren's syndrome"", 'miR-1248']",[''],2019,Zheng ChangYu,,"Molecular Physiology and Therapeutics, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.",,,National Institutes of Health,grid.94365.3d,True
31597594,Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.,"['Interferon', 'RIG-I and ITPR3', ""Sjögren's syndrome"", 'miR-1248']",[''],2019,Warner Blake M,,"Sjögren's Syndrome and Salivary Gland Dysfunction Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.",,,National Institutes of Health,grid.94365.3d,True
31597594,Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.,"['Interferon', 'RIG-I and ITPR3', ""Sjögren's syndrome"", 'miR-1248']",[''],2019,Alevizos Ilias,alevizosi@mail.nih.gov,"Sjögren's Syndrome and Salivary Gland Dysfunction Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. Electronic address: alevizosi@mail.nih.gov.",,,National Institutes of Health,grid.94365.3d,True
31594442,A case report of Sjögren's syndrome associated with protein-losing gastroenteropathy successfully treated with methylprednisolone.,"['99mTc-labelled albumin scintigraphy', 'Protein-losing enteropathy', 'case report', 'immunosuppressive drugs', 'primary Sjögren’s syndrome']",[''],2019,Li Xiaoming,,"Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Provincial Institute of Clinical Geriatrics, Fujian Provincial Key Laboratory of Geriatric Diseases, Fujian Medical University, Fuzhou, China.",,China,Fujian Provincial Hospital,grid.415108.9,True
31594442,A case report of Sjögren's syndrome associated with protein-losing gastroenteropathy successfully treated with methylprednisolone.,"['99mTc-labelled albumin scintigraphy', 'Protein-losing enteropathy', 'case report', 'immunosuppressive drugs', 'primary Sjögren’s syndrome']",[''],2019,Lin Fan,,"Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Provincial Institute of Clinical Geriatrics, Fujian Provincial Key Laboratory of Geriatric Diseases, Fujian Medical University, Fuzhou, China.",,China,Fujian Provincial Hospital,grid.415108.9,True
31594442,A case report of Sjögren's syndrome associated with protein-losing gastroenteropathy successfully treated with methylprednisolone.,"['99mTc-labelled albumin scintigraphy', 'Protein-losing enteropathy', 'case report', 'immunosuppressive drugs', 'primary Sjögren’s syndrome']",[''],2019,Wu Ziyu,,"Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Provincial Institute of Clinical Geriatrics, Fujian Provincial Key Laboratory of Geriatric Diseases, Fujian Medical University, Fuzhou, China.",,China,Fujian Provincial Hospital,grid.415108.9,True
31594442,A case report of Sjögren's syndrome associated with protein-losing gastroenteropathy successfully treated with methylprednisolone.,"['99mTc-labelled albumin scintigraphy', 'Protein-losing enteropathy', 'case report', 'immunosuppressive drugs', 'primary Sjögren’s syndrome']",[''],2019,Chen Yan,,"Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Provincial Institute of Clinical Geriatrics, Fujian Provincial Key Laboratory of Geriatric Diseases, Fujian Medical University, Fuzhou, China.",,China,Fujian Provincial Hospital,grid.415108.9,True
31594442,A case report of Sjögren's syndrome associated with protein-losing gastroenteropathy successfully treated with methylprednisolone.,"['99mTc-labelled albumin scintigraphy', 'Protein-losing enteropathy', 'case report', 'immunosuppressive drugs', 'primary Sjögren’s syndrome']",[''],2019,Zhu Pengli,,"Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Provincial Institute of Clinical Geriatrics, Fujian Provincial Key Laboratory of Geriatric Diseases, Fujian Medical University, Fuzhou, China.",,China,Fujian Provincial Hospital,grid.415108.9,True
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Xie M M,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Zou R Y,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Li Y,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Liu Y,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Chen L L,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Liu X Q,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Zhao Q,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Ding J J,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Chen Z Y,,"Department of rheumatism immunology, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31594111,[Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].,"['Anti-synthetase antibody', 'Connective tissue disease', 'Lung disease, interstitial', 'Polymyositis/dermatomyositis (PM/DM)']","['D000328', 'D000368', 'D001323', 'D001324', 'D002681', 'D003240', 'D003882', 'D005260', 'D006801', 'D017563', 'D008297', 'D008875', 'D009220', 'D017285', 'D012698']",2019,Cai H R,,"Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.",21000,China,,,False
31592858,Distinct Salivary Gland Features in Sjögren's Syndrome and Lupus Erythematosus Sialadenite.,[''],[''],2019,Bologna Sheyla B,,"Department of Stomatology, Dental School, University of Sao Paulo, Sao Paulo, Brazil.",,Brazil,University of Sao Paulo,grid.11899.38,True
31592858,Distinct Salivary Gland Features in Sjögren's Syndrome and Lupus Erythematosus Sialadenite.,[''],[''],2019,Cavalcante Wanessa S,,"Department of Dermatology, Medical School, University of Sao Paulo, Sao Paulo, Brazil. Dr. Souza is now with the International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.",,Brazil,,,False
31592858,Distinct Salivary Gland Features in Sjögren's Syndrome and Lupus Erythematosus Sialadenite.,[''],[''],2019,Florezi Giovanna P,,"Department of Stomatology, Dental School, University of Sao Paulo, Sao Paulo, Brazil.",,Brazil,University of Sao Paulo,grid.11899.38,True
31592858,Distinct Salivary Gland Features in Sjögren's Syndrome and Lupus Erythematosus Sialadenite.,[''],[''],2019,Souza Milena M,,"Department of Dermatology, Medical School, University of Sao Paulo, Sao Paulo, Brazil. Dr. Souza is now with the International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.",,Brazil,,,False
31592858,Distinct Salivary Gland Features in Sjögren's Syndrome and Lupus Erythematosus Sialadenite.,[''],[''],2019,Nico Marcello M S,,"Department of Dermatology, Medical School, University of Sao Paulo, Sao Paulo, Brazil. Dr. Souza is now with the International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.",,Brazil,,,False
31592858,Distinct Salivary Gland Features in Sjögren's Syndrome and Lupus Erythematosus Sialadenite.,[''],[''],2019,Lourenço Silvia V,,"Department of Stomatology, Dental School, University of Sao Paulo, Sao Paulo, Brazil.",,Brazil,University of Sao Paulo,grid.11899.38,True
31586984,[Late-onset sjögren's syndrom].,"['  late-onset', ' Sjögren’s syndrome', ' comorbidity ', ' the elderly']","['D000328', 'D017668', 'D000368', 'D057210', 'D006801', 'D008875', 'D012859']",2019,Koszarny Arkadiusz,,"Klinika Reumatologii i Układowych Chorób Tkanki Łącznej, Uniwersytet Medyczny w Lublinie, Lublin, Polska.",,,,,False
31586984,[Late-onset sjögren's syndrom].,"['  late-onset', ' Sjögren’s syndrome', ' comorbidity ', ' the elderly']","['D000328', 'D017668', 'D000368', 'D057210', 'D006801', 'D008875', 'D012859']",2019,Górak Anna,,"Klinika Reumatologii i Układowych Chorób Tkanki Łącznej, Uniwersytet Medyczny w Lublinie, Lublin, Polska.",,,,,False
31586984,[Late-onset sjögren's syndrom].,"['  late-onset', ' Sjögren’s syndrome', ' comorbidity ', ' the elderly']","['D000328', 'D017668', 'D000368', 'D057210', 'D006801', 'D008875', 'D012859']",2019,Majdan Maria,,"Klinika Reumatologii i Układowych Chorób Tkanki Łącznej, Uniwersytet Medyczny w Lublinie, Lublin, Polska.",,,,,False
31585842,Suspected inflammatory rheumatic diseases in patients presenting with skin rashes.,"['Autoantibodies', 'Dermatology', 'Dermatomyositis', 'Psoriasis', 'Rheumatology', ""Sjögren's syndrome"", 'Skin', ""Still's disease"", 'Systemic lupus erythematosus', 'Systemic sclerosis']",[''],2019,Alves Francisca,,"Clinic of Dermatology, University Hospital of Coimbra, Portugal.",,Portugal,,,False
31585842,Suspected inflammatory rheumatic diseases in patients presenting with skin rashes.,"['Autoantibodies', 'Dermatology', 'Dermatomyositis', 'Psoriasis', 'Rheumatology', ""Sjögren's syndrome"", 'Skin', ""Still's disease"", 'Systemic lupus erythematosus', 'Systemic sclerosis']",[''],2019,Gonçalo Margarida,mgoncalo@fmed.uc.pt,"Clinic of Dermatology, University Hospital of Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal. Electronic address: mgoncalo@fmed.uc.pt.",,Portugal,,,False
31583215,A Rare Case of Renal AA Amyloidosis Secondary to Sjogren's Syndrome.,"['AA amyloidosis', 'Sjogren’s syndrome', 'renal amyloidosis', 'renal biopsy']",[''],2019,Costa Mylene,,"Internal Medicine, Hospital Pedro Hispano, Porto, Portugal.",,Portugal,,,False
31583215,A Rare Case of Renal AA Amyloidosis Secondary to Sjogren's Syndrome.,"['AA amyloidosis', 'Sjogren’s syndrome', 'renal amyloidosis', 'renal biopsy']",[''],2019,Greenfield Helena,,"Internal Medicine, Hospital Pedro Hispano, Porto, Portugal.",,Portugal,,,False
31583215,A Rare Case of Renal AA Amyloidosis Secondary to Sjogren's Syndrome.,"['AA amyloidosis', 'Sjogren’s syndrome', 'renal amyloidosis', 'renal biopsy']",[''],2019,Pereira Ricardo,,"Internal Medicine, Hospital Pedro Hispano, Porto, Portugal.",,Portugal,,,False
31583215,A Rare Case of Renal AA Amyloidosis Secondary to Sjogren's Syndrome.,"['AA amyloidosis', 'Sjogren’s syndrome', 'renal amyloidosis', 'renal biopsy']",[''],2019,Chuva Teresa,,"Nephrology, Instituto Português de Oncologia do Porto, Portugal.",,Portugal,,,False
31583215,A Rare Case of Renal AA Amyloidosis Secondary to Sjogren's Syndrome.,"['AA amyloidosis', 'Sjogren’s syndrome', 'renal amyloidosis', 'renal biopsy']",[''],2019,Henrique Rui,,"Pathological Anatomy, Instituto Português de Oncologia do Porto, Portugal.",,Portugal,,,False
31583215,A Rare Case of Renal AA Amyloidosis Secondary to Sjogren's Syndrome.,"['AA amyloidosis', 'Sjogren’s syndrome', 'renal amyloidosis', 'renal biopsy']",[''],2019,Cunha Cátia,,"Nephrology, Hospital Pedro Hispano, Porto, Portugal.",,Portugal,,,False
31578802,Insights into IL-29: Emerging role in inflammatory autoimmune diseases.,"['autoimmunity', 'inflammation', 'interleukin-29', 'signalling']",[''],2019,Wang Jia-Min,,"Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, Sichuan, China.",,China,,,False
31578802,Insights into IL-29: Emerging role in inflammatory autoimmune diseases.,"['autoimmunity', 'inflammation', 'interleukin-29', 'signalling']",[''],2019,Huang An-Fang,,"Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, Sichuan, China.",,China,Affiliated Hospital of Southwest Medical University,grid.488387.8,True
31578802,Insights into IL-29: Emerging role in inflammatory autoimmune diseases.,"['autoimmunity', 'inflammation', 'interleukin-29', 'signalling']",[''],2019,Xu Wang-Dong,,"Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, Sichuan, China.",,China,,,False
31578802,Insights into IL-29: Emerging role in inflammatory autoimmune diseases.,"['autoimmunity', 'inflammation', 'interleukin-29', 'signalling']",[''],2019,Su Lin-Chong,,"Department of Rheumatology and Immunology, Minda Hospital of Hubei Minzu University, Enshi, China.",,China,,,False
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Zhao Rui,,"Department of Nursing, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, 226001, China.",22600,China,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Wang Yilin,,"Department of Nursing, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, 226001, China.",22600,China,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Zhou Wei,,"Department of Nursing, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, 226001, China.",22600,China,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Guo Jiaxin,,"Department of Nursing, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, 226001, China.",22600,China,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,He Mei,,"Department of Nursing, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, 226001, China.",22600,China,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Li Ping,,"Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 20th Xisi Road, 226001, Nantong, People's Republic of China.",22600,,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Gao Jianlin,,"Research Center of Gerontology and Longevity, Affiliated Hospital of Nantong University, Nantong, China.",,China,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Gu Zhifeng,guzf@ntu.edu.cn,"Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 20th Xisi Road, 226001, Nantong, People's Republic of China. guzf@ntu.edu.cn.",22600,,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Gu Zhifeng,guzf@ntu.edu.cn,"Research Center of Gerontology and Longevity, Affiliated Hospital of Nantong University, Nantong, China. guzf@ntu.edu.cn.",,China,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Gu Zhifeng,guzf@ntu.edu.cn,"Department of Rheumatology, Affiliated Hospital of Nantong University, 20th Xisi Road, 226001, Nantong, People's Republic of China. guzf@ntu.edu.cn.",22600,,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Dong Chen,dongchensc@126.com,"Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 20th Xisi Road, 226001, Nantong, People's Republic of China. dongchensc@126.com.",22600,,Nantong University,grid.260483.b,True
31578648,Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren's syndrome.,"['China', 'Interstitial lung disease', 'Primary Sjögren’s syndrome', 'Quality of life']",[''],2019,Dong Chen,dongchensc@126.com,"Research Center of Gerontology and Longevity, Affiliated Hospital of Nantong University, Nantong, China. dongchensc@126.com.",,China,Nantong University,grid.260483.b,True
31578131,Nodular localized primary cutaneous amyloidosis and primary Sjögren's syndrome.,[''],[''],2019,Davies K,,"Department of Rheumatology, Institute of Cellular Medicine, Newcastle University , Newcastle upon Tyne , UK.",,,Newcastle University,grid.1006.7,True
31578131,Nodular localized primary cutaneous amyloidosis and primary Sjögren's syndrome.,[''],[''],2019,Collins A,,"Department of Rheumatology, Institute of Cellular Medicine, Newcastle University , Newcastle upon Tyne , UK.",,,Newcastle University,grid.1006.7,True
31578131,Nodular localized primary cutaneous amyloidosis and primary Sjögren's syndrome.,[''],[''],2019,Charlton F G,,"Cellular Pathology, Royal Victoria Infirmary , Newcastle upon Tyne , UK.",,,Royal Victoria Infirmary,grid.419334.8,True
31578131,Nodular localized primary cutaneous amyloidosis and primary Sjögren's syndrome.,[''],[''],2019,Ng W-F,,"Department of Rheumatology, Institute of Cellular Medicine, Newcastle University , Newcastle upon Tyne , UK.",,,Newcastle University,grid.1006.7,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Sakakida T,,"Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji agaru, Kawaramachi Street, Kamigyoku, Kyoto, 602-8566, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Ishikawa T,t@koto.kpu,"Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji agaru, Kawaramachi Street, Kamigyoku, Kyoto, 602-8566, Kyoto, Japan. iskw-t@koto.kpu-m.ac.jp.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Ishikawa T,t@koto.kpu,"Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan. iskw-t@koto.kpu-m.ac.jp.",,Japan,Kyoto Prefectural University of Medicine,grid.272458.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Chihara Y,,"Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,Kyoto Prefectural University of Medicine,grid.272458.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Chihara Y,,"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Harita S,,"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Uchino J,,"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Tabuchi Y,,"Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,Kyoto Prefectural University of Medicine,grid.272458.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Tabuchi Y,,"Department of Hospital Pharmacy, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,Kyoto Prefectural University of Medicine,grid.272458.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Komori S,,"Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Asai J,,"Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Narukawa T,,"Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,Department of Virology,grid.462718.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Arai A,,"Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Tsunezuka H,,"Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Kosuga T,,"Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Konishi H,,"Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Moriguchi M,,"Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji agaru, Kawaramachi Street, Kamigyoku, Kyoto, 602-8566, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Yasuda H,,"Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji agaru, Kawaramachi Street, Kamigyoku, Kyoto, 602-8566, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Hongo F,,"Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,Department of Virology,grid.462718.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Inoue M,,"Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Hirano S,,"Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Ukimura O,,"Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,Department of Virology,grid.462718.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Itoh Y,,"Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji agaru, Kawaramachi Street, Kamigyoku, Kyoto, 602-8566, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Taguchi T,,"Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,Kyoto Prefectural University of Medicine,grid.272458.e,True
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Taguchi T,,"Division of Endocrine and Breast Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31576495,Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.,"['Antinuclear antibodies', 'Autoimmune diseases', 'Immune checkpoint inhibitors', 'Immune-related adverse events', 'Programmed cell death 1 blockade']",[''],2019,Takayama K,,"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.",,Japan,,,False
31572659,Bilateral corneal melting associated with topical diclofenac 0.1% after cataract surgery in a patient with Sjögren's syndrome.,"['Amniotic membrane', ""Sjögren's syndrome"", 'corneal ulcer', 'nonsteroidal anti-inflammatory agents', 'phacoemulsification']",[''],,Tu Pei-Ning,,"Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan.",,,Cathay General Hospital,grid.413535.5,True
31572659,Bilateral corneal melting associated with topical diclofenac 0.1% after cataract surgery in a patient with Sjögren's syndrome.,"['Amniotic membrane', ""Sjögren's syndrome"", 'corneal ulcer', 'nonsteroidal anti-inflammatory agents', 'phacoemulsification']",[''],,Hou Yu-Chih,,"Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan.",,,Cathay General Hospital,grid.413535.5,True
31572659,Bilateral corneal melting associated with topical diclofenac 0.1% after cataract surgery in a patient with Sjögren's syndrome.,"['Amniotic membrane', ""Sjögren's syndrome"", 'corneal ulcer', 'nonsteroidal anti-inflammatory agents', 'phacoemulsification']",[''],,Hou Yu-Chih,,"Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.",,,National Taiwan University,grid.19188.39,True
31572659,Bilateral corneal melting associated with topical diclofenac 0.1% after cataract surgery in a patient with Sjögren's syndrome.,"['Amniotic membrane', ""Sjögren's syndrome"", 'corneal ulcer', 'nonsteroidal anti-inflammatory agents', 'phacoemulsification']",[''],,Hou Yu-Chih,,"Department of Ophthalmology, College of Medicine, Fu Jen Catholic University, 510, New Taipei City, Taiwan.",,,Fu Jen Catholic University,grid.256105.5,True
31572650,Update on the role of impression cytology in ocular surface disease.,"['Blepharitis', 'conjunctiva', 'diagnosis', 'dry eye', 'impression cytology', 'inflammation', 'medical device', 'review']",[''],,Thia Zhang-Zhe,,"Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.",,Singapore,National University of Singapore,grid.4280.e,True
31572650,Update on the role of impression cytology in ocular surface disease.,"['Blepharitis', 'conjunctiva', 'diagnosis', 'dry eye', 'impression cytology', 'inflammation', 'medical device', 'review']",[''],,Tong Louis,,"Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.",,Singapore,National University of Singapore,grid.4280.e,True
31572650,Update on the role of impression cytology in ocular surface disease.,"['Blepharitis', 'conjunctiva', 'diagnosis', 'dry eye', 'impression cytology', 'inflammation', 'medical device', 'review']",[''],,Tong Louis,,"Corneal and External Eye Disease Service, Singapore National Eye Center, Singapore.",,Singapore,Singapore National Eye Center,grid.419272.b,True
31572650,Update on the role of impression cytology in ocular surface disease.,"['Blepharitis', 'conjunctiva', 'diagnosis', 'dry eye', 'impression cytology', 'inflammation', 'medical device', 'review']",[''],,Tong Louis,,"Singapore Eye Research Institute, Singapore.",,Singapore,Singapore Eye Research Institute,grid.272555.2,True
31572650,Update on the role of impression cytology in ocular surface disease.,"['Blepharitis', 'conjunctiva', 'diagnosis', 'dry eye', 'impression cytology', 'inflammation', 'medical device', 'review']",[''],,Tong Louis,,"Eye-academic Clinical Program, Duke-NUS Medical School, Singapore.",,Singapore,,,False
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Segerberg Filip,,"Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.",,Sweden,Karolinska Institute,grid.4714.6,True
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Lundtoft Christian,,"Rheumatology and Science for Life Laboratories, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Reid Sarah,,"Rheumatology and Science for Life Laboratories, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Hjorton Karin,,"Rheumatology and Science for Life Laboratories, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Leonard Dag,,"Rheumatology and Science for Life Laboratories, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Nordmark Gunnel,,"Rheumatology and Science for Life Laboratories, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Carlsten Mattias,,"Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.",,Sweden,Karolinska Institute,grid.4714.6,True
31572377,Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.,"['autoantibody', 'killer cell immunoglobulin-like receptor', 'natural killer cells', 'nephritis', ""primary Sjögren's syndrome"", 'systemic lupus erythematosus']",[''],2019,Hagberg Niklas,,"Rheumatology and Science for Life Laboratories, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.",,Sweden,Uppsala University,grid.8993.b,True
31570207,Non- Hodgkin lymphoma of the lips: A rare entity.,"['Lip', 'Lymphoma', 'MALT', 'Malignancy', 'Oral mucosa']",[''],2019,Kaplan I,dr.ilanakaplan@gmail.com,"Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; Rabin Medical Center, Petah-Tikva, Israel; Goldschleger School of Dental Medicine, Tel-Aviv University, Israel; Sackler School of Medicine, Tel-Aviv University, Israel. Electronic address: dr.ilanakaplan@gmail.com.",,Israel,Tel Aviv University,grid.12136.37,True
31570207,Non- Hodgkin lymphoma of the lips: A rare entity.,"['Lip', 'Lymphoma', 'MALT', 'Malignancy', 'Oral mucosa']",[''],2019,Shuster A,,"Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; Goldschleger School of Dental Medicine, Tel-Aviv University, Israel.",,Israel,Tel Aviv University,grid.12136.37,True
31570207,Non- Hodgkin lymphoma of the lips: A rare entity.,"['Lip', 'Lymphoma', 'MALT', 'Malignancy', 'Oral mucosa']",[''],2019,Frenkel G,,"Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.",,Israel,,,False
31570207,Non- Hodgkin lymphoma of the lips: A rare entity.,"['Lip', 'Lymphoma', 'MALT', 'Malignancy', 'Oral mucosa']",[''],2019,Avishai G,,"Rabin Medical Center, Petah-Tikva, Israel.",,Israel,,,False
31570207,Non- Hodgkin lymphoma of the lips: A rare entity.,"['Lip', 'Lymphoma', 'MALT', 'Malignancy', 'Oral mucosa']",[''],2019,Allon I,,"Barzilai Medical Center, Ben-Gurion University Ashkelon, Beer Sheva, Israel.",,Israel,Barzilai Medical Center,grid.414259.f,True
31570207,Non- Hodgkin lymphoma of the lips: A rare entity.,"['Lip', 'Lymphoma', 'MALT', 'Malignancy', 'Oral mucosa']",[''],2019,Raiser V,,"Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.",,Israel,,,False
31566227,The first case of monozygotic twin boys with nearly identical features of Sjögren's syndrome.,[''],[''],2019,Thatayatikom Akaluck,,"Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, College of Medicine.",,,,,False
31566227,The first case of monozygotic twin boys with nearly identical features of Sjögren's syndrome.,[''],[''],2019,Bhattacharyya Indraneel,,Division of Oral Pathology.,,,,,False
31566227,The first case of monozygotic twin boys with nearly identical features of Sjögren's syndrome.,[''],[''],2019,Elder Melissa E,,"Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, College of Medicine.",,,,,False
31566227,The first case of monozygotic twin boys with nearly identical features of Sjögren's syndrome.,[''],[''],2019,Cha Seunghee,,"Division of Oral Medicine, Department of Oral & Maxillofacial Diagnostic Sciences, College of Dentistry, University of Florida, Gainesville, FL, USA.",,,University of Florida,grid.15276.37,True
31566079,Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.,"['Neuromyelitis optica spectrum disorder', ""Sjögren's syndrome"", 'aquaporin-4', 'overlap syndromes', 'systemic lupus erythematosus']",[''],2019,Martín-Nares E,,"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.",,Mexico,,,False
31566079,Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.,"['Neuromyelitis optica spectrum disorder', ""Sjögren's syndrome"", 'aquaporin-4', 'overlap syndromes', 'systemic lupus erythematosus']",[''],2019,Hernandez-Molina G,,"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.",,Mexico,,,False
31566079,Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.,"['Neuromyelitis optica spectrum disorder', ""Sjögren's syndrome"", 'aquaporin-4', 'overlap syndromes', 'systemic lupus erythematosus']",[''],2019,Fragoso-Loyo H,,"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.",,Mexico,,,False
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Huang Chuan,,"Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong, 510006, China.",51000,China,University of Technology,grid.483960.0,True
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Zhu Hao-Xian,,"Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong, 510006, China.",51000,China,University of Technology,grid.483960.0,True
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Yao Yuan,,"Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, 510006, China.",51000,China,University of Technology,grid.483960.0,True
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Bian Zhen-Hua,,"Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, 510006, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong, 510006, China.",51000,China,University of Technology,grid.483960.0,True
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Zheng Yu-Jian,,"Center of Transplantation, General Hospital of Southern Theatre Command of PLA, Guangzhou, Guangdong, 510010, China.",51001,China,,,False
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Li Liang,lil2009@scut.edu.cn,"Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, 510006, China. Electronic address: lil2009@scut.edu.cn.",51000,China,University of Technology,grid.483960.0,True
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Moutsopoulos Haralampos M,,"National University of Athens, 11527, Athens, Greece.",11527,Greece,,,False
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Gershwin M Eric,,"National University of Athens, 11527, Athens, Greece; Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, CA, USA.",11527,Greece,,,False
31564474,Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.,[''],[''],2019,Lian Zhe-Xiong,zxlian@scut.edu.cn,"Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, 510006, China. Electronic address: zxlian@scut.edu.cn.",51000,China,University of Technology,grid.483960.0,True
31562704,The Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases.,"['IL-18', 'IL-1β', 'autoimmune diseases', 'inflammasome']",[''],2019,Kahlenberg J Michelle,,"Division of Rheumatology, University of Michigan.",,,,,False
31562704,The Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases.,"['IL-18', 'IL-1β', 'autoimmune diseases', 'inflammasome']",[''],2019,Kang Insoo,,"Section of Rheumatology, Allergy and Immunology, Yale University.",,,Yale University,grid.47100.32,True
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Nixon Jane,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Brown Sarah,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Smith Isabelle L,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,McGinnis Elizabeth,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,McGinnis Elizabeth,,"Research and Innovation, Leeds Teaching Hospitals NHS Trust, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Vargas-Palacios Armando,,"Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.",,,University of Leeds,grid.9909.9,True
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Nelson E Andrea,,"School of Healthcare, University of Leeds, Leeds, UK.",,,University of Leeds,grid.9909.9,True
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Nelson E Andrea,,"School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.",,,Glasgow Caledonian University,grid.5214.2,True
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Brown Julia,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Coleman Susanne,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Collier Howard,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Fernandez Catherine,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Gilberts Rachael,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Henderson Valerie,,"Independent Tissue Viability Consultant, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,McCabe Christopher,,"Institute of Health Economics, Edmonton, AB, Canada.",,Canada,Institute of Health Economics,grid.414721.5,True
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Muir Delia,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Rutherford Claudia,,"Quality of Life Office, Psycho-oncology Co-operative Research Group, The University of Sydney, Sydney, NSW, Australia.",,Australia,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Stubbs Nikki,,"Neighbourhood Team North 1, Leeds Community Healthcare NHS Trust, Leeds, UK.",,,Leeds Community Healthcare NHS Trust,grid.439761.e,True
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Thorpe Benjamin,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Wallner Klemens,,"Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.",,Canada,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Walker Kay,,"Pressure Ulcer Research Service User Network, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Wilson Lyn,,"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Wilson Lyn,,"Research and Innovation, Mid Yorkshire Hospitals NHS Trust, Wakefield, UK.",,,,,False
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Hulme Claire,,"Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.",,,University of Leeds,grid.9909.9,True
31559948,Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT.,"['ALTERNATING PRESSURE MATTRESS', 'COST–BENEFIT ANALYSIS', 'HIGH SPECIFICATION FOAM MATTRESS', 'PRESSURE ULCER', 'QUALITY OF LIFE', 'RANDOMISED CONTROLLED TRIAL']",[''],2019,Hulme Claire,,"Health Economics Group, Institute of Health Research, University of Exeter Medical School, Exeter, UK.",,,,,False
31559183,Diagnostic value of major salivary gland ultrasonography in primary Sjögren's syndrome: the role of grey-scale and colour/power Doppler sonography.,"['Salivary gland ultrasonography (SGUS)', 'Sjögren’s syndrome (SS)', 'colour/power Doppler sonography (C/PDUS)']",[''],2019,Carotti Marina,,"Azienda Ospedaliera Universitaria, Ospedali Riuniti di Ancona, Dipartimento di Scienze Radiologiche S. O. D. Radiologia Pediatrica e Specialistica, Ancona (AN), Italy.",,Italy,,,False
31559183,Diagnostic value of major salivary gland ultrasonography in primary Sjögren's syndrome: the role of grey-scale and colour/power Doppler sonography.,"['Salivary gland ultrasonography (SGUS)', 'Sjögren’s syndrome (SS)', 'colour/power Doppler sonography (C/PDUS)']",[''],2019,Salaffi Fausto,,"Clinica Reumatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona (AN), Italy.",,Italy,,,False
31559183,Diagnostic value of major salivary gland ultrasonography in primary Sjögren's syndrome: the role of grey-scale and colour/power Doppler sonography.,"['Salivary gland ultrasonography (SGUS)', 'Sjögren’s syndrome (SS)', 'colour/power Doppler sonography (C/PDUS)']",[''],2019,Di Carlo Marco,,"Clinica Reumatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona (AN), Italy.",,Italy,,,False
31559183,Diagnostic value of major salivary gland ultrasonography in primary Sjögren's syndrome: the role of grey-scale and colour/power Doppler sonography.,"['Salivary gland ultrasonography (SGUS)', 'Sjögren’s syndrome (SS)', 'colour/power Doppler sonography (C/PDUS)']",[''],2019,Barile Antonio,,"Dipartimento di Radiodiagnostica, Ospedale S. Salvatore, Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università degli Studi dell'Aquila, L'Aquila (AQ), Italy.",,Italy,,,False
31559183,Diagnostic value of major salivary gland ultrasonography in primary Sjögren's syndrome: the role of grey-scale and colour/power Doppler sonography.,"['Salivary gland ultrasonography (SGUS)', 'Sjögren’s syndrome (SS)', 'colour/power Doppler sonography (C/PDUS)']",[''],2019,Giovagnoni Andrea,,"Azienda Ospedaliera Universitaria, Ospedali Riuniti di Ancona, Dipartimento di Scienze Radiologiche S. O. D. Radiologia Pediatrica e Specialistica, Ancona (AN), Italy.",,Italy,,,False
31559092,Dry Eye Indexes Estimated by Keratograph 5M of Systemic Lupus Erythematosus Patients without Secondary Sjögren's Syndrome Correlate with Lupus Activity.,[''],[''],2019,Wang An,,"Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.",23002,China,First Affiliated Hospital of Anhui Medical University,grid.412679.f,True
31559092,Dry Eye Indexes Estimated by Keratograph 5M of Systemic Lupus Erythematosus Patients without Secondary Sjögren's Syndrome Correlate with Lupus Activity.,[''],[''],2019,Gu Zhengyu,,"Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.",23002,China,First Affiliated Hospital of Anhui Medical University,grid.412679.f,True
31559092,Dry Eye Indexes Estimated by Keratograph 5M of Systemic Lupus Erythematosus Patients without Secondary Sjögren's Syndrome Correlate with Lupus Activity.,[''],[''],2019,Liao Rongfeng,,"Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.",23002,China,First Affiliated Hospital of Anhui Medical University,grid.412679.f,True
31559092,Dry Eye Indexes Estimated by Keratograph 5M of Systemic Lupus Erythematosus Patients without Secondary Sjögren's Syndrome Correlate with Lupus Activity.,[''],[''],2019,Shuai Zongwen,,"Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.",23002,China,First Affiliated Hospital of Anhui Medical University,grid.412679.f,True
31557796,Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.,"['Sjogren’s syndrome (ss)', 'autoimmune diseases', 'biologic therapy', 'bone marrow', 'cell extract', 'lacrimal gland', 'mesenchymal stem cells (MSCs)', 'non-obese diabetic mice (NOD)', 'salivary glands', 'submandibular glands']",[''],2019,Abughanam Ghada,ghada.abuelghanam@mail.mcgill.ca,"McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of Dentistry, McGill University, Montreal, QC H3A 0C7, Canada. ghada.abuelghanam@mail.mcgill.ca.",H3A 0C7,Canada,McGill University,grid.14709.3b,True
31557796,Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.,"['Sjogren’s syndrome (ss)', 'autoimmune diseases', 'biologic therapy', 'bone marrow', 'cell extract', 'lacrimal gland', 'mesenchymal stem cells (MSCs)', 'non-obese diabetic mice (NOD)', 'salivary glands', 'submandibular glands']",[''],2019,Elkashty Osama A,osama.elkashty@mail.mcgill.ca,"McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of Dentistry, McGill University, Montreal, QC H3A 0C7, Canada. osama.elkashty@mail.mcgill.ca.",H3A 0C7,Canada,McGill University,grid.14709.3b,True
31557796,Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.,"['Sjogren’s syndrome (ss)', 'autoimmune diseases', 'biologic therapy', 'bone marrow', 'cell extract', 'lacrimal gland', 'mesenchymal stem cells (MSCs)', 'non-obese diabetic mice (NOD)', 'salivary glands', 'submandibular glands']",[''],2019,Liu Younan,Younan.liu@mcgill.ca,"McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of Dentistry, McGill University, Montreal, QC H3A 0C7, Canada. Younan.liu@mcgill.ca.",H3A 0C7,Canada,McGill University,grid.14709.3b,True
31557796,Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.,"['Sjogren’s syndrome (ss)', 'autoimmune diseases', 'biologic therapy', 'bone marrow', 'cell extract', 'lacrimal gland', 'mesenchymal stem cells (MSCs)', 'non-obese diabetic mice (NOD)', 'salivary glands', 'submandibular glands']",[''],2019,Bakkar Mohammed O,mob11@case.edu,"McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of Dentistry, McGill University, Montreal, QC H3A 0C7, Canada. mob11@case.edu.",H3A 0C7,Canada,McGill University,grid.14709.3b,True
31557796,Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.,"['Sjogren’s syndrome (ss)', 'autoimmune diseases', 'biologic therapy', 'bone marrow', 'cell extract', 'lacrimal gland', 'mesenchymal stem cells (MSCs)', 'non-obese diabetic mice (NOD)', 'salivary glands', 'submandibular glands']",[''],2019,Tran Simon D,simon.tran@mcgill.ca,"McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of Dentistry, McGill University, Montreal, QC H3A 0C7, Canada. simon.tran@mcgill.ca.",H3A 0C7,Canada,McGill University,grid.14709.3b,True
31556344,"Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.",[''],[''],2019,Heus A,,"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.",,,,,False
31556344,"Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.",[''],[''],2019,Heus A,,"Department of Radiology, Medical Spectrum Twente , Enschede , The Netherlands.",,,,,False
31556344,"Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.",[''],[''],2019,Arends S,,"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.",,,,,False
31556344,"Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.",[''],[''],2019,Van Nimwegen J F,,"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.",,,,,False
31556344,"Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.",[''],[''],2019,Stel A J,,"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.",,,,,False
31556344,"Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.",[''],[''],2019,Nossent G D,,"Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.",,,,,False
31556344,"Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.",[''],[''],2019,Bootsma H,,"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.",,,,,False
